Effect of sodium zirconium cyclosilicate in combination with insulin and glucose infusion on hyperkalemia treatment

Abstract

Purpose: To evaluate the efficacy of sodium zirconium cyclosilicate (SZC) in combination with insulinand glucose infusion in managing hyperkalemia. Methods: A total of 126 patients, who were admitted with hyperkalemia (≥ 5 mmol/L) to the Yongchuan District Hospital of Traditional  Chinese Medicine, Chongqing, China from January 2021 to December 2022, were retrospectively studied. Participants were divided into  three groups based on different potassium-lowering regimens, viz, SZC group (40 patients), insulin with glucose (IG) group (38 patients) and SZC + IG group (48 patients). Changes in potassium levels, other serum electrolytes (magnesium, sodium, phosphate, calcium),  alanine aminotransferase (ALT) and albumin before and after treatment were recorded. Adverse reactions during treatment were also  recorded. Results: Post-treatment, the potassium levels in all three groups exhibited a significant reduction when compared to pre- treatment values (p < 0.05). The SZC + IG group showed the highest efficacy, with a significant reduction in blood potassium levels  observed 4 h after administration, which was more pronounced compared to other groups. The SZC + IG group, maintained potassium  ion concentration at a normal level for a longer duration and no serious adverse reactions were observed during treatment. Conclusion:  Intervention with SZC + IG lowers blood potassium levels, maintains it within normal range, and is more effective than the individual use  of SZC or IG. A combination of sodium zirconium cyclosilicate, insulin and glucose infusion for treating hyperkalemia will need to be  investigated further in a large-scale multicenter study.